(UroToday.com) The safety of active surveillance for grade group 2 patients is debated, in that it has been evaluated in several single-center studies with mixed results.1-2 At the American Urological Association (AUA) annual virtual meeting, Dr. Adrian J. Waisman Malaret and colleagues presented results of their study assessing the clinical outcomes of men with grade group 1 and grade group 2 prostate cancer undergoing active surveillance in the Canary Prostate Cancer Active Surveillance Study (PASS) cohort.